

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM693309

|   |  |                       |  |
|---|--|-----------------------|--|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                           |                       |  |
| <b>NATURE OF CONVEYANCE:</b>  | RELEASE OF SECURITY INTEREST             |                       |  |
| <b>CONVEYING PARTY DATA</b>   |  |                       |  |
| <b>Name</b>   | <b>Formerly</b>                          | <b>Execution Date</b> | <b>Entity Type</b>                             |
| JPMorgan Chase Bank, N.A.,<br>as Collateral Agent   |  | 12/08/2021            | National Banking Association:<br>UNITED STATES |
| <b>RECEIVING PARTY DATA</b>   |  |                       |  |
| <b>Name:</b>  | Pharmaco Investments, Inc.               |                       |  |
| <b>Street Address:</b>  | 929 North Front Street                   |                       |  |
| <b>City:</b>  | Wilmington                               |                       |  |
| <b>State/Country:</b>   | NORTH CAROLINA                           |                       |  |
| <b>Postal Code:</b>   | 28401                                    |                       |  |
| <b>Entity Type:</b>   | Corporation: DELAWARE                    |                       |  |
| <b>PROPERTY NUMBERS Total: 5</b>  |  |                       |  |
| <b>Property Type</b>  | <b>Number</b>                            | <b>Word Mark</b>      |  |
| <b>Registration Number:</b>   | 2435414                                  | PPD                   |  |
| <b>Registration Number:</b>   | 2332213                                  | PPD                   |  |
| <b>Registration Number:</b>   | 2644316                                  | PPD QUERYDIRECT       |  |
| <b>Registration Number:</b>   | 4573756                                  | PRECLARUS             |  |
| <b>Registration Number:</b>   | 4787158                                  | TRIMENTUM             |  |
| <b>CORRESPONDENCE DATA</b>  |  |                       |  |
| <b>Fax Number:</b>  | 2127514864                               |                       |  |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |  |                       |  |
| <b>Phone:</b>   | 2129061216                               |                       |  |
| <b>Email:</b>   | angela.amaru@lw.com                      |                       |  |
| <b>Correspondent Name:</b>  | Latham & Watkins LLP c/o Angela M. Amaru |                       |  |
| <b>Address Line 1:</b>  | 1271 Avenue of the Americas              |                       |  |
| <b>Address Line 4:</b>  | New York, NEW YORK 10020                 |                       |  |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 045494-0325                              |                       |  |
| <b>NAME OF SUBMITTER:</b>   | Angela M. Amaru                          |                       |  |
| <b>SIGNATURE:</b>   | /s/ Angela M. Amaru                      |                       |  |
| <b>DATE SIGNED:</b>   | 12/08/2021                               |                       |  |

CH \$140.00 2435414

**Total Attachments: 4**

source=PPD - Trademark Release - 2021 TSA (Executed Version) (128228633.1)#page1.tif

source=PPD - Trademark Release - 2021 TSA (Executed Version) (128228633.1)#page2.tif

source=PPD - Trademark Release - 2021 TSA (Executed Version) (128228633.1)#page3.tif

source=PPD - Trademark Release - 2021 TSA (Executed Version) (128228633.1)#page4.tif

**RELEASE OF SECURITY INTEREST IN TRADEMARKS**

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this “Release”), dated as of December 8, 2021 (the “Effective Date”), is made by JPMORGAN CHASE BANK, N.A., as collateral agent (in such capacity, the “Agent”), in favor of EVIDERA, INC., and PHARMACO INVESTMENTS, INC., ACURIAN, INC., MEDICIGROUP, INC., OPTIMAL RESEARCH, LLC and SYNEXUS CLINICAL RESEARCH US, INC. (each a “Grantor” and collectively, the “Grantors”). All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Trademark Security Agreement (whether defined therein or by reference to another agreement).

WHEREAS, pursuant to that certain Security Agreement by and among the Grantors, the Agent, and certain other parties, dated as of January 13, 2021 (as may have been amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), the Grantors executed and delivered a Trademark Security Agreement, dated as of January 13, 2021 (the “Trademark Security Agreement”), which was recorded in the United States Patent and Trademark Office (“USPTO”) on January 13, 2021 at Reel/Frame 7161/0169 (with respect to Synexus Clinical Research US, Inc.), at Reel/Frame 7235/0672 (with respect to Pharmaco Investments, Inc.), at Reel/Frame 7161/0179 (with respect to Optimal Research, LLC), at Reel/Frame 7161/0382 (with respect to MediciGroup, Inc.), at Reel/Frame 7161/0402 (with respect to Evidera, Inc.), and at Reel/Frame 7161/0159 (with respect to Acurian, Inc.);

WHEREAS, pursuant to the Security Agreement and the Trademark Security Agreement, each Grantor collaterally assigned, pledged and granted to the Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on (the “Security Interest”) all of such Grantor’s right, title and interest in and to (i) all trademarks, service marks, and applications therefor, including those set forth on Schedule A hereto; (ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals and reexaminations thereof; (iii) any and all claims for damages or injunctive relief for past, present and future infringement, dilution, misappropriation, violation or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and (iv) all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto; but excluding any Excluded Property (collectively, the “Trademark Collateral”);

WHEREAS, the Grantors have requested the Agent to release the Security Interest in the Trademark Collateral.


NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent, hereby (i) terminates the Trademark Security Agreement, (ii) releases, discharges, terminates and cancels the Security Interest in the Trademark Collateral, and (iii) re-assigns to each Grantor any right, title or interest it may have in the Trademark Collateral of such Grantor, in each case without recourse to the Agent and without representation or warranty of any kind.

Each Grantor, or any successor to such Grantor (including any person or entity hereafter holding any right, title or interest in or to the Trademark Collateral of such Grantor), is hereby authorized to record this Release in the USPTO.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the Agent has caused this Release to be executed and delivered by its duly authorized officer as of the Effective Date.

JPMORGAN CHASE BANK, N.A., as Collateral Agent

By:   
Name: Jason Hur  
Title: Executive Director



[PPD, Inc. - JPM Trademark Release]

TRADEMARK  
REEL: 007523 FRAME: 0604

**SCHEDULE A**

**Trademarks**

**I. Registered Trademarks**

| Owner                              | Mark  | Registration Number | Country | Expiration Date |
|------------------------------------|---|---------------------|---------|-----------------|
| Pharmaco Investments, Inc.         | "PPD" (Word Mark)   | 2,435,414           | USA     | Mar. 13, 2031   |
| Pharmaco Investments, Inc.         | "PPD" (Stylized)  | 2,332,313           | USA     | Mar. 21, 2030   |
| Pharmaco Investments, Inc.         | "PPD QUERYDIRECT"   | 2,644,316           | USA     | Oct. 29, 2022   |
| Pharmaco Investments, Inc.         | "PRECLARUS"   | 4,573,756           | USA     | Jul. 22, 2024   |
| Pharmaco Investments, Inc.         | "TRIMENTUM"   | 4,787,158           | USA     | Aug. 4, 2025    |
| Acurian, Inc.                      | "ACURIAN RECRUITMENT MANAGER"   | 3,971,039           | USA     | May 31, 2021    |
| Acurian, Inc.                      | "ACURIAN" (Plus Design)   | 2,697,439           | USA     | Mar. 18, 2023   |
| Acurian, Inc.                      | "ACURIAN"   | 2,566,246           | USA     | Apr. 30, 2022   |
| Acurian, Inc.                      | "ACURIAN HEALTH"  | 4,411,824           | USA     | Oct. 1, 2023    |
| Acurian, Inc.                      |   | 4,429,550           | USA     | Nov. 5, 2023    |
| Acurian, Inc.                      | "ACURIAN RETENTION MANAGER"   | 4,621,574           | USA     | Oct. 14, 2024   |
| SYNEXUS CLINICAL RESEARCH US, INC. |  | 6,128,809           | USA     | Aug. 18, 2030   |
| Optimal Research, LLC              | OPTIMAL RESEARCH INTEGRATED SITE SOLUTIONS  | 5,129,408           | USA     | Jan. 24, 2027   |
| Evidera, Inc.                      | "E-RS"  | 4,959,657           | USA     | May 17, 2026    |
| Evidera, Inc.                      | "EVIDERA" + Design  | 4,555,020           | USA     | Jun. 24, 2024   |
| Evidera, Inc.                      | "EVIDERA"   | 4,555,019           | USA     | Jun. 24, 2024   |
| Evidera, Inc.                      | "EXACT-PRO INITIATIVE" + Design   | 4,728,703           | USA     | Apr. 28, 2025   |
| Evidera, Inc.                      | "EVIDICE"   | 5,141,280           | USA     | Feb. 14, 2027   |
| Evidera, Inc.                      | "IVALUE SUITE"  | 5,154,972           | USA     | Mar. 7, 2027    |
| Evidera, Inc.                      | "ReVIDICE"  | 5,150,411           | USA     | Feb. 28, 2027   |
| Evidera, Inc.                      | "THE EVIDENCE FORUM"  | 5,252,789           | USA     | Jul. 25, 2027   |
| Evidera, Inc.                      | "EVIDERA" + Design  | 5,487,857           | USA     | Jan. 5, 2028    |

| Owner                                  | Mark                           | Registration Number | Country | Expiration Date |
|--|--------------------------------|---------------------|---------|-----------------|
| MediciGroup, Inc.                      | WORLDS APART, PURPLE TOGETHER  | 4,735,643           | USA     | May 12, 2025    |
| MediciGroup, Inc.                      | TEAM EPILEPSY                  | 4,160,281           | USA     | Jun. 19, 2022   |
| MediciGroup, Inc.                      | STUDYCOORDINATOR.NET           | 3,987,441           | USA     | Jun. 28, 2021   |
| MediciGroup, Inc.                      | L2FU                           | 4,018,286           | USA     | Aug. 30, 2021   |
| MediciGroup, Inc.                      | CENTER FOR PATIENT RECRUITMENT | 2,956,002           | USA     | May 24, 2025    |
| MediciGroup, Inc.                      | HEAD START TO RECRUITMENT      | 3,867,150           | USA     | Oct. 26, 2020   |
| MediciGroup, Inc.                      | MEDICIGLOBAL + Design          | 3,864,845           | USA     | Oct. 19, 2020   |
| MediciGroup, Inc.                      | STUDY SEMINARS                 | 2,515,932           | USA     | Dec. 4, 2021    |
| MediciGroup, Inc.                      | VIP                            | 2,445,248           | USA     | Apr. 17, 2021   |
| MediciGroup, Inc.                      | CTIP                           | 2,360,017           | USA     | Jun. 20, 2020   |
| MediciGroup, Inc.                      | MEDICIGROUP                    | 2,131,963           | USA     | Jan. 27, 2028   |
| MediciGroup, Inc.                      | SMART                          | 2,902,264           | USA     | Nov. 9, 2024    |
| Evidera, Inc. (f/k/a Fieldaccess, LLC) | LIVETRACKER                    | 4,950,468           | USA     | May 3, 2022     |
| Evidera, Inc. (f/k/a Fieldaccess, LLC) | MEDIMIX                        | 3,138,599           | USA     | Oct. 17, 2026   |

II. Trademark Applications

None.